Universal Biosensors, Inc. (ASX:UBI)

Market Cap	5.96M
Revenue (ttm)	6.37M
Net Income (ttm)	-14.64M
Shares Out	298.07M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	303,766
Average Volume	84,893
Open	0.0200
Previous Close	0.0200
Day's Range	0.0190 - 0.0200
52-Week Range	0.0180 - 0.1600
Beta	0.85
RSI	18.01
Earnings Date	Aug 8, 2025

About Universal Biosensors

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO₂, malic acid, glucose, fructose, total acid, and titratable acid...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 76
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: UBI

Financial Performance

In 2024, Universal Biosensors's revenue was 6.28 million, a decrease of -5.28% compared to the previous year's 6.63 million. Losses were -14.24 million, 111.2% more than in 2023.